Citalax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citalax

Citalax is a pharmaceutical preparation classified as an antidepressant and belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) pharmacological class, designed to support overall mood regulation by influencing specific chemical pathways in the brain.

Property Description
Active ingredient Escitalopram (S-enantiomer)
Form Film-coated tablet, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Mood regulation, emotional stability
Origin Synthetic, Single isomer

What Type of Medicine is Citalax?

Citalax is an antidepressant of the SSRI class, a category of medicine widely utilized to help regulate emotional stability and psychological well-being. Escitalopram is a highly selective inhibitor of serotonin reuptake, providing a clear pharmacological profile. This classification indicates that the drug's effect is highly focused, primarily targeting the Serotonin system in the Central Nervous System (CNS). The general therapeutic purpose of this class is to assist in restoring a balanced neurotransmission state, often clinically recognized for its role in supporting the return to daily functioning for adults.


Escitalopram: Composition and Form

The active ingredient in Citalax is Escitalopram, a synthetic compound that is chemically defined as the pure S-enantiomer. Escitalopram is distinct as a single isomer product, meaning it represents the specific, active component of its older related racemic compound, Citalopram. As a single active ingredient product, Citalax is prepared for oral administration and is available in high-level dosage forms, including the film-coated tablet and the oral solution, offering flexibility for different patient consumption preferences.


The Core Action of Serotonin Reuptake Inhibition

The basis of Citalax’s effect is its highly selective action on the Serotonin (5-HT) system, specifically through the inhibition of Serotonin reuptake. This action prevents the reabsorption of Serotonin by nerve cells, thereby increasing the concentration of the neurotransmitter available for communication between neurons. This mechanism helps restore Serotonin balance in the brain. This selective potentiation of serotonergic activity is the foundational mechanism that allows the medicine to exert its general function in supporting mood regulation.

Regulatory References

  1. MedlinePlus: Escitalopram

What side effects are possible with Citalax?

Possible side effects and safety information

The safety profile of Citalax (Escitalopram) is organized according to regulatory classifications, defining potential adverse reactions by frequency and the body system affected.

Adverse Reaction Classification

Side effects are categorized based on their official incidence rate documented in regulatory sources:

Frequency Classification Examples of Documented Effects
Very Common (ge 1/10) Nausea, Headache, Insomnia, Somnolence (Drowsiness)
Common (ge 1/100 to < 1/10) Fatigue, Diarrhea, Dry mouth, Increased sweating, Decreased appetite, Anxiety, Sexual dysfunction

These effects are grouped into System-Organ Classes (SOCs), including Nervous System disorders, Gastrointestinal disorders, and Psychiatric disorders.

Serious Adverse Reactions and Safety Constraints

The official safety information highlights specific, potentially serious reactions that require attention. These include the risk of Serotonin Syndrome, certain cardiac rhythm disturbances such as QTc prolongation and Ventricular Arrhythmia (Torsade de Pointes), and severe Hyponatraemia (low sodium levels).

Population-Specific and Time-Related Safety Notes:

  • Young Adults (under 25): The label notes an increased risk of suicidal ideation and behavior when starting treatment or adjusting the dosage.
  • Older Adults: Specific risks, including a higher potential for Hyponatraemia and bleeding events, are documented.
  • Contraindications: Use is strictly prohibited for individuals with congenital long QT syndrome or other known QTc interval prolongation, reflecting a key safety limitation.

The regulatory framework ensures all documented safety information, ranging from common effects to rare but serious constraints, is clearly delineated.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose with Citalax (Escitalopram) requires immediate medical attention. Contact emergency services or a poison control center if symptoms of overdose are observed, particularly if the person collapses, experiences a seizure, or cannot be awakened.

Overdose manifestations documented in regulatory labeling often affect the central nervous system, cardiovascular system, and gastrointestinal tract.

System Affected Documented Signs and Symptoms
CNS Dizziness, tremor, somnolence, agitation, and convulsions.
Cardiovascular Tachycardia, bradycardia, hypotension, and ECG changes (QT/QRS prolongation).
Gastrointestinal Nausea and vomiting.

Severe and potentially life-threatening outcomes are documented in regulatory sources, including Serotonin Syndrome and progression to coma. The documented cardiac effects, such as QT prolongation, carry the risk of severe arrhythmias like Torsades de Pointes. The majority of severe or fatal outcomes have been associated with the concomitant ingestion of multiple drugs.

Regulatory guidance states that no specific antidote is known for Escitalopram overdose. Management is symptomatic and supportive, requiring continuous monitoring of vital signs and cardiac rhythm (ECG monitoring). Emergency response procedures may include establishing an airway and considering decontamination measures like gastric lavage or activated charcoal.

Therapeutic Uses of Citalax

What Citalax Treats: Main Uses and Benefits

Citalax is commonly used across domains where additional symptomatic support is needed to provide supportive relief and supports general well-being during symptomatic phases. It is relevant in clinical settings marked by heightened patient distress and symptoms that interfere with daily functioning.

The medication is generally applied in addressing conditions associated with acute or disruptive episodes of mood and anxiety, specifically Major Depressive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Social Anxiety Disorder. It also may assist with the symptomatic burden of Obsessive-Compulsive Disorder. The overall therapeutic goal is to help patients cope more steadily with difficult episodes by easing distress and managing the symptoms related to heightened physiological activity. The medication is applied when groups of symptoms appear suddenly or fluctuate, providing support that helps ease the overall symptom burden.

The support provided by Citalax contributes to maintaining a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases, assisting with maintaining functional stability. This approach is often used during phases when symptoms become more noticeable and supportive relief is needed.


Quick Fact: Support for Pervasive Worry
Citalax is considered relevant for easing excessive, uncontrollable worry and the associated physical tension characteristic of chronic anxiety states. It helps manage the symptoms that interfere with daily comfort.

Regulatory References

  1. NIH MedlinePlus overview on Escitalopram

Eligibility and Restrictions for Use

Who Can and Cannot Use Citalax?

This section defines the official population eligibility rules for Citalax (Escitalopram) as stated in government regulatory documents.

Contraindicated Populations

Citalax must not be used by individuals with a known hypersensitivity to the drug or citalopram. Use is absolutely prohibited concurrently with Monoamine Oxidase Inhibitors (MAOIs) or Pimozide. Regulatory documents also state the medicine is contraindicated in patients with known QT interval prolongation or when taking other medicines that prolong the QT interval.

Age and Organ Function Restrictions

Eligibility for adults is established. For pediatric patients, use is defined by specific age floors (e.g., 12 years for Major Depressive Disorder), with safety and effectiveness not established below these minimum ages. Some regulatory authorities state the medicine should not be used in adolescents under 18 for depression.

Use is restricted in older adults and those with hepatic impairment, as the maximum recommended dose must be lower. Caution is advised for patients with severe renal impairment and those with a history of seizures or mania/hypomania.

Reproductive Status

Eligibility is conditional for pregnant women and nursing mothers; the official label requires that use must only proceed if the potential benefit justifies the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify certain combinations with Citalax (Escitalopram) as restricted or prohibited based on pharmacokinetic and pharmacodynamic outcomes. This section describes the documented interaction profile.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, is strictly prohibited due to the risk of severe serotonergic reactions. A mandatory 14-day washout period must separate the use of Citalax and an MAOI intended for psychiatric disorders. Combining Citalax with Pimozide or any other medicinal product known to prolong the QT interval is also contraindicated.

Other Documented Interaction Risks

Interaction Type Interacting Substance Class Official Regulatory Outcome
Pharmacodynamic Serotonergic Agents (e.g., Triptans, Tramadol) Increased risk of Serotonin Syndrome.
Pharmacodynamic Anticoagulants/NSAIDs Increased risk of abnormal bleeding.
Pharmacokinetic CYP2D6 Substrates (e.g., Desipramine) Increased exposure (AUC/Cmax) of the co-administered drug.
Pharmacokinetic CYP2C19 Inhibitors (e.g., Omeprazole) Documented increase in Escitalopram plasma concentration.

Citalax's absorption is not affected by food. Concomitant use with alcohol and St. John’s Wort is generally not recommended due to documented interaction potential.

Mechanism of Action

Citalax (Citalopram) acts primarily within the central nervous system by targeting the serotonin transporter (SERT), a protein also known as the solute carrier family 6 member 4 (SLC6A4). It functions as a selective serotonin reuptake inhibitor (SSRI). Citalax binds to the orthosteric site on the presynaptic SERT protein, competitively inhibiting the reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft back into the presynaptic neuron.

This interaction results in an acute elevation of extracellular 5-HT concentration in the synaptic space. The sustained increase in synaptic 5-HT concentration leads to a cascade of downstream neuroadaptive changes. These consequences include the gradual desensitization and downregulation of somatodendritic 5-HT1A autoreceptors, which normally inhibit 5-HT release. This desensitization permits greater subsequent 5-HT release into the synapse. Chronic action also promotes intracellular signaling cascades involving factors like Brain-Derived Neurotrophic Factor (BDNF), which is associated with altered neurogenesis and neuroplasticity within specific brain regions.

Dosage and Administration Information

Citalax (Escitalopram) is administered exclusively through the oral route, available as both a film-coated tablet and an oral solution. The procedural guidelines for its use establish a standardized intake pattern.

The standard administration pattern requires the medicine be taken once daily, with no strict requirement regarding mealtimes; it may be taken with or without food. The usual starting dose for adults is 10 mg, increasing to a maximum daily dose of 20 mg. Dose adjustments, if required, should only occur after the initial dose has been maintained for a minimum of one week.


Administration Guidelines

Instruction Entity Statement
Route of administration Oral (via tablet or oral solution).
Standard Maximum Dose 20 mg once daily.
Population Dosing (Max) 10 mg for older adults (65+) and hepatic impairment.
Discontinuation Rule Gradual dose reduction (tapering) is required over 1–2 weeks.

The oral solution must be measured using a calibrated device to ensure dose accuracy, while scored tablets may be divided. Use is classified as a long-term therapy that requires periodic reassessment. The administration framework emphasizes a controlled, once-daily intake pattern and defines a specific process for dose adjustment and eventual cessation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Citalax

Citalax was evaluated through formal clinical research, primarily using Randomized Controlled Trials (RCTs). This section provides an overview of the types of studies conducted and what the resulting evidence contributes to the broader understanding of symptom patterns, without offering clinical instruction or advice.


Evidence for Use in Major Depressive Disorder (MDD)

Research for Citalax in MDD primarily involved numerous short-term RCTs. These studies were used in research exploring how symptoms change over time and involved comparisons against both a placebo (sugar pill) and sometimes other active treatments. The main outcomes measured in these trials were changes in standardized severity rating scales (e.g., MADRS, HAMD), to track whether participants were categorized as reaching a clinical response or remission.

Studies conducted during periods of increased symptom activity reported patterns of score changes across observed populations. The active agent group's measured scores were observed to differ from the placebo group's scores over the acute treatment phase, typically 8 to 12 weeks. Subsequent maintenance trials monitored the time elapsed before the return of symptoms in the observed groups.

Evidence for Use in Anxiety and Panic Conditions

Citalax was evaluated in studies for several conditions, including Generalized Anxiety Disorder (GAD), Panic Disorder (PD), and Social Anxiety Disorder (SAD). For GAD, research focused on short-term RCTs, where outcomes related to excessive worry and physical tension were evaluated. Findings described patterns where standardized scores were observed to change during the study period in comparison with placebo.

For Panic Disorder, controlled trials tracked changes in the frequency of panic attacks. Findings described patterns where the active agent group's reported average frequency of attacks was observed to be different from that of the placebo group. The evidence base is largely formed by a limited number of research trials.

What Remains Uncertain in the Research

Research provides context but not individual predictions. The primary research limitations include the fact that follow-up durations were limited across many indications, especially regarding outcomes measured over multiple years. While research for the core indications of MDD and GAD is primarily based on high-rigor study designs, the volume of controlled research is smaller for conditions like Panic Disorder and OCD. Finally, subgroup findings remain uncertain in some areas, as sample sizes were modest for trials involving certain special populations.

Frequently Asked Questions (FAQ)

Common questions about Citalax (FAQ)


Q: What is the main difference between Citalax and other common similar drugs?

According to official product information, the active ingredient in Citalax is Escitalopram. It is described as the S-enantiomer of its related compound, citalopram, meaning it represents the single, specific active component of that older drug. This gives it a focused pharmacological profile.


Q: Why do doctors prescribe Citalax?

Official regulatory documents state that Citalax is indicated for the treatment of Major Depressive Disorder (MDD) in adults and adolescents, and Generalized Anxiety Disorder (GAD) in adults. These are the conditions for which the drug has official indications.


Q: How quickly does Citalax usually start to work?

Official information notes that any necessary dose adjustments should be considered after maintaining the initial dose for a minimum of one week. Clinical trials typically assess outcomes over an acute treatment period of 8 to 12 weeks to evaluate patterns of change.


Q: What is the expected length of time Citalax treatment usually lasts?

Treatment is often classified as a long-term therapy designed to support mood stability. Regulatory guidance emphasizes that the prescribing health professional should periodically re-evaluate the long-term usefulness for each person receiving treatment.


Q: Is Citalax known to be habit-forming or addictive?

Citalax is not classified as a controlled substance by regulatory agencies in the U.S. and is generally described in official information as having no recognized abuse potential. Regulatory information emphasizes that gradual dose reduction is necessary when stopping the medication to manage the potential for discontinuation symptoms.


Q: Can Citalax cause changes in appetite?

Yes, changes in appetite are documented in official sources. A decreased appetite is listed as a common side effect (ge 1/100 to < 1/10). Additionally, increased appetite has been documented in post-marketing experience.


Q: What should I know about Citalax and weight gain?

Regulatory sources, including some international monographs, list an increase in weight as a documented adverse reaction. This is one of the effects recorded during post-marketing surveillance and clinical trials.


Q: Is it common to feel tired when first starting Citalax?

Yes, this can occur in the initial phase. Official documents list Fatigue and Somnolence (drowsiness) as very common or common side effects. These effects are commonly reported when treatment is initiated.


Q: Why do some people say Citalax caused them to feel 'wired' or agitated?

Anxiety and Restlessness are listed as common side effects in the official product information. Additionally, the regulatory label notes a risk for the Activation of Mania/Hypomania. This is an officially noted risk that requires careful attention.


Q: Is Citalax considered a long-term treatment option?

Yes, Citalax is often used for long-term therapy. Clinical studies have supported the benefit of maintenance treatment, meaning continuing the drug after a person has initially responded. Prescribers are still advised to periodically re-evaluate the drug's necessity over time.


Q: What happens if I forget to take a dose of Citalax?

Official patient information advises that you should not take a double dose to make up for a forgotten dose. This regulatory guidance highlights the importance of consistent, once-daily intake.


Q: What is the common experience when stopping Citalax?

Stopping the drug requires a gradual dose reduction (tapering). The symptoms described in regulatory documents may include dizziness, abnormal dreams, agitation, and sensory disturbances such as electric shock sensations.


Q: How does Citalax compare to similar medications regarding research evidence?

Citalax is described in official documents as having a high degree of selectivity compared to its class of similar drugs. Clinical trials have been conducted against both placebo and other active treatments to establish its effectiveness for approved uses.


Q: What common foods or drinks might interact with Citalax?

Official regulatory notes advise caution or avoidance when using the drug alongside alcohol and grapefruit juice.


Q: Are there any known issues with Citalax and liver function?

Yes, regulatory documents note that for individuals with hepatic impairment (reduced liver function), a lower maximum daily dose is required. This is due to the potential for the body to clear the drug more slowly.


Q: What information do regulatory sources provide about long-term Citalax use?

Systematic maintenance trials have shown that the drug supports long-term stability for those who respond well to initial treatment. Nevertheless, the prescriber is advised to periodically re-evaluate whether continued use is appropriate.


Q: Is it normal for side effects to come and go in the first few weeks?

Official patient information from regulatory bodies notes that side effects are often mild and may disappear after a few days as the body adjusts to the medicine. If side effects persist or are concerning, the advice is to contact a healthcare provider.


Q: What are the known potential interactions with grapefruit juice?

Grapefruit juice is noted in some official product information as an inhibitor of certain enzymes that process the drug. For this reason, caution or avoidance is advised due to the theoretical risk of increased Citalax levels in the body.


Q: What research exists on Citalax's use in the elderly?

Specific research and regulatory guidance exist for older patients (aged 65 and over). This population has an officially defined maximum dose that is lower than the general adult population, and is noted to have a higher risk for certain side effects, including low sodium levels (Hyponatraemia) and bleeding events.


Q: Does Citalax affect alertness?

Yes, Citalax has the potential to affect alertness. Official warnings describe that the drug may cause drowsiness and interfere with judgment, thinking, or motor skills.


Q: What kind of studies support the use of Citalax?

The primary evidence supporting the use of Citalax is formed by numerous rigorous studies. These include Randomized Controlled Trials (RCTs) to assess initial effectiveness and subsequent maintenance trials to study long-term benefits.


Q: Can Citalax affect my ability to drive or operate machinery?

Regulatory warnings suggest caution is necessary when operating machinery or driving until a person is certain the medicine does not impair their ability.


Q: What are the requirements for monitoring while taking Citalax?

Regulatory warnings require that patients must be closely monitored, especially during the start of therapy or during dosage adjustments. This monitoring focuses on changes in behavior, clinical worsening, or the emergence of suicidal thoughts.


Q: Can Citalax be taken with common pain relievers like ibuprofen?

Regulatory documents note that combining Citalax with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, is associated with an increased risk of abnormal bleeding.


Q: Are there any common over-the-counter medicines that interact with Citalax?

Interactions are documented for the drug class Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen. Additionally, the herbal supplement St. John's Wort, which is widely available, is known to interact.


Q: Can Citalax affect heart rhythm or cause palpitations?

Yes, serious official warnings note the risk of QTc prolongation, which is a change in the heart's electrical rhythm. There is also a risk of a potentially life-threatening ventricular arrhythmia, reflecting a need for caution.


Q: What information is available about Citalax use during pregnancy?

Regulatory documents state that use during pregnancy must only be considered if the potential benefit justifies the potential risk to the fetus. This conditional guidance highlights the need for a careful risk-benefit discussion with a prescriber.


Q: Is Citalax suitable for use while breastfeeding?

Official labeling advises caution. The decision to use the medicine while nursing requires consideration of the importance of the drug to the mother, and the documented passage of the active ingredient into breast milk.


Q: Can Citalax be prescribed to adolescents or teenagers?

The drug is officially indicated for the treatment of Major Depressive Disorder in pediatric patients 12 years of age and older. However, some regulatory authorities have issued guidance advising against its use for depression in those under 18.


Q: Can Citalax be taken with blood pressure medication?

Caution is advised for people taking certain blood pressure medications, particularly diuretics ('water pills'). Regulatory warnings note the possibility of low sodium levels (Hyponatraemia) when taken with diuretics, requiring awareness of this documented safety concern.


Q: Does Citalax cause sexual side effects?

Yes, sexual side effects are common. Regulatory documents list decreased libido (sex drive), ejaculation disorder (often delayed ejaculation), and anorgasmia (inability to reach orgasm) as common adverse reactions.


Q: What is the role of Citalax in managing anxiety?

Beyond depression, Citalax is officially indicated for the treatment of Generalized Anxiety Disorder (GAD) in adults. Clinical studies also include research into its use for other conditions such as Panic Disorder.


Q: What is the research evidence for Citalax's approved uses?

Clinical trials for approved uses, such as Major Depressive Disorder and Generalized Anxiety Disorder, demonstrated that outcomes measured by standardized severity scales showed patterns of change in the study populations compared to placebo groups over the acute treatment phase.

How should Citalax be stored and disposed of?

How to Store and Dispose of Citalax

Citalax (Escitalopram) must be stored according to official regulatory conditions to maintain its labeled stability. The medicine must be kept at Controlled Room Temperature, which is between 20 C to 25 C (68 F to 77 F), with brief excursions permitted up to 30 C.

Storage and Protection

The product must be stored in its original container and kept tightly closed. It requires protection from moisture and light. The oral solution is explicitly labeled with the instruction to not be frozen. All forms of Citalax must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired medication should be disposed of in accordance with government guidelines. This often involves taking it to a local drug take-back program or following instructions for secure household trash disposal, which advises against discarding it in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citalax found in:

A-Z Index: